Literature DB >> 25818337

Clinical and molecular characterization of patients with heterozygous mutations in wilms tumor suppressor gene 1.

Anja Lehnhardt1, Claartje Karnatz2, Thurid Ahlenstiel-Grunow2, Kerstin Benz2, Marcus R Benz2, Klemens Budde2, Anja K Büscher2, Thomas Fehr2, Markus Feldkötter2, Norbert Graf2, Britta Höcker2, Therese Jungraithmayr2, Günter Klaus2, Birgit Koehler2, Martin Konrad2, Birgitta Kranz2, Carmen R Montoya2, Dominik Müller2, Thomas J Neuhaus2, Jun Oh2, Lars Pape2, Martin Pohl2, Brigitte Royer-Pokora2, Uwe Querfeld2, Reinhard Schneppenheim2, Hagen Staude2, Giuseppina Spartà2, Kirsten Timmermann2, Frauke Wilkening2, Simone Wygoda2, Carsten Bergmann2, Markus J Kemper2.   

Abstract

BACKGROUND AND OBJECTIVES: The Wilms tumor suppressor gene 1 (WT1) plays an essential role in urogenital and kidney development. Genotype/phenotype correlations of WT1 mutations with renal function and proteinuria have been observed in world-wide cohorts with nephrotic syndrome or Wilms tumor (WT). This study analyzed mid-European patients with known constitutional heterozygous mutations in WT1, including patients without proteinuria or WT. DESIGN, SETTING, PARTICIPANTS & MEASUREMENTS: Retrospective analysis of genotype, phenotype, and treatment of 53 patients with WT1 mutation from all pediatric nephrology centers in Germany, Austria, and Switzerland performed from 2010 to 2012.
RESULTS: Median age was 12.4 (interquartile range [IQR], 6-19) years. Forty-four of 53 (83%) patients had an exon mutation (36 missense, eight truncating), and nine of 53 (17%) had an intronic lysine-threonine-serine (KTS) splice site mutation. Fifty of 53 patients (94%) had proteinuria, which occurred at an earlier age in patients with missense mutations (0.6 [IQR, 0.1-1.5] years) than in those with truncating (9.7 [IQR, 5.7-11.9]; P<0.001) and splice site (4.0 [IQR, 2.6-6.6]; P=0.004) mutations. Thirteen of 50 (26%) were treated with steroids and remained irresponsive, while three of five partially responded to cyclosporine A. Seventy-three percent of all patients required RRT, those with missense mutations significantly earlier (at 1.1 [IQR, 0.01-9.3] years) than those with truncating mutations (16.5 [IQR, 16.5-16.8]; P<0.001) and splice site mutations (12.3 [IQR, 7.9-18.2]; P=0.002). Diffuse mesangial sclerosis was restricted to patients with missense mutations, while focal segmental sclerosis occurred in all groups. WT occurred only in patients with exon mutations (n=19). Fifty of 53 (94%) patients were karyotyped: Thirty-one (62%) had XY and 19 (38%) had XX chromosomes, and 96% of male karyotypes had urogenital malformations.
CONCLUSIONS: Type and location of WT1 mutations have predictive value for the development of proteinuria, renal insufficiency, and WT. XY karyotype was more frequent and associated with urogenital malformations in most cases.
Copyright © 2015 by the American Society of Nephrology.

Entities:  

Keywords:  genetic renal disease; nephrotic syndrome; pediatric nephrology

Mesh:

Year:  2015        PMID: 25818337      PMCID: PMC4422247          DOI: 10.2215/CJN.10141014

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  30 in total

1.  GONADOBLASTOMA ASSOCIATED WITH PURE GONADAL DYSGENESIS IN MONOZYGOUS TWINS.

Authors:  S D FRASIER; R A BASHORE; H D MOSIER
Journal:  J Pediatr       Date:  1964-05       Impact factor: 4.406

2.  WT1 gene mutations in three girls with nephrotic syndrome.

Authors:  Khalid Ismaili; Véronique Verdure; Katherina Vandenhoute; Françoise Janssen; Michelle Hall
Journal:  Eur J Pediatr       Date:  2007-06-01       Impact factor: 3.183

3.  Focal and segmental glomerulosclerosis: definition and relevance of a partial remission.

Authors:  Stéphan Troyanov; Catherine A Wall; Judith A Miller; James W Scholey; Daniel C Cattran
Journal:  J Am Soc Nephrol       Date:  2005-02-16       Impact factor: 10.121

4.  Genotype/phenotype correlation in nephrotic syndrome caused by WT1 mutations.

Authors:  Gil Chernin; Virginia Vega-Warner; Dominik S Schoeb; Saskia F Heeringa; Bugsu Ovunc; Pawaree Saisawat; Roxana Cleper; Fatih Ozaltin; Friedhelm Hildebrandt
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 8.237

5.  End stage renal disease in patients with Wilms tumor: results from the National Wilms Tumor Study Group and the United States Renal Data System.

Authors:  Norman E Breslow; Allan J Collins; Michael L Ritchey; Yevgeny A Grigoriev; Susan M Peterson; Daniel M Green
Journal:  J Urol       Date:  2005-11       Impact factor: 7.450

6.  WT1-mediated transcriptional activation is inhibited by dominant negative mutant proteins.

Authors:  J C Reddy; J C Morris; J Wang; M A English; D A Haber; Y Shi; J D Licht
Journal:  J Biol Chem       Date:  1995-05-05       Impact factor: 5.157

7.  A novel WT1 gene mutation in a three-generation family with progressive isolated focal segmental glomerulosclerosis.

Authors:  Elisa Benetti; Gianluca Caridi; Cristina Malaventura; Monica Dagnino; Emanuela Leonardi; Lina Artifoni; Gian Marco Ghiggeri; Silvio C E Tosatto; Luisa Murer
Journal:  Clin J Am Soc Nephrol       Date:  2010-02-11       Impact factor: 8.237

8.  A zinc finger truncation of murine WT1 results in the characteristic urogenital abnormalities of Denys-Drash syndrome.

Authors:  C E Patek; M H Little; S Fleming; C Miles; J P Charlieu; A R Clarke; K Miyagawa; S Christie; J Doig; D J Harrison; D J Porteous; A J Brookes; M L Hooper; N D Hastie
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

9.  Donor splice-site mutations in WT1 are responsible for Frasier syndrome.

Authors:  S Barbaux; P Niaudet; M C Gubler; J P Grünfeld; F Jaubert; F Kuttenn; C N Fékété; N Souleyreau-Therville; E Thibaud; M Fellous; K McElreavey
Journal:  Nat Genet       Date:  1997-12       Impact factor: 38.330

Review 10.  The many facets of the Wilms' tumour gene, WT1.

Authors:  Peter Hohenstein; Nicholas D Hastie
Journal:  Hum Mol Genet       Date:  2006-10-15       Impact factor: 6.150

View more
  15 in total

1.  Structural Chromosomal Rearrangements Require Nucleotide-Level Resolution: Lessons from Next-Generation Sequencing in Prenatal Diagnosis.

Authors:  Zehra Ordulu; Tammy Kammin; Harrison Brand; Vamsee Pillalamarri; Claire E Redin; Ryan L Collins; Ian Blumenthal; Carrie Hanscom; Shahrin Pereira; India Bradley; Barbara F Crandall; Pamela Gerrol; Mark A Hayden; Naveed Hussain; Bibi Kanengisser-Pines; Sibel Kantarci; Brynn Levy; Michael J Macera; Fabiola Quintero-Rivera; Erica Spiegel; Blair Stevens; Janet E Ulm; Dorothy Warburton; Louise E Wilkins-Haug; Naomi Yachelevich; James F Gusella; Michael E Talkowski; Cynthia C Morton
Journal:  Am J Hum Genet       Date:  2016-10-13       Impact factor: 11.025

2.  Genotype-phenotype analysis of pediatric patients with WT1 glomerulopathy.

Authors:  Yo Han Ahn; Eu Jin Park; Hee Gyung Kang; Seong Heon Kim; Hee Yeon Cho; Jae Il Shin; Joo Hoon Lee; Young Seo Park; Kyo Sun Kim; Il-Soo Ha; Hae Il Cheong
Journal:  Pediatr Nephrol       Date:  2016-06-14       Impact factor: 3.714

3.  Amenorrhea in a pediatric kidney transplant recipient: Answers.

Authors:  Benjamin Steinman; Stella Kilduff; Marcela Del Rio; Nicole Hayde
Journal:  Pediatr Nephrol       Date:  2021-11-03       Impact factor: 3.714

Review 4.  [Tumor predisposition syndromes and nephroblastoma : Early diagnosis with imaging].

Authors:  N Welter; R Furtwängler; G Schneider; N Graf; J-P Schenk
Journal:  Radiologie (Heidelb)       Date:  2022-08-25

Review 5.  Isolated steroid-resistant nephrotic syndrome in a Chinese child carrying a de novo mutation in WT1 gene:a case report and literature review.

Authors:  Yiyang Li; Chuan Tian; Yajun Wang; Guoda Ma; Riling Chen
Journal:  BMC Pediatr       Date:  2022-06-16       Impact factor: 2.567

Review 6.  Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma.

Authors:  Jennifer M Kalish; Leslie Doros; Lee J Helman; Raoul C Hennekam; Roland P Kuiper; Saskia M Maas; Eamonn R Maher; Kim E Nichols; Sharon E Plon; Christopher C Porter; Surya Rednam; Kris Ann P Schultz; Lisa J States; Gail E Tomlinson; Kristin Zelley; Todd E Druley
Journal:  Clin Cancer Res       Date:  2017-07-01       Impact factor: 12.531

7.  Rapid Response to Cyclosporin A and Favorable Renal Outcome in Nongenetic Versus Genetic Steroid-Resistant Nephrotic Syndrome.

Authors:  Anja K Büscher; Bodo B Beck; Anette Melk; Julia Hoefele; Birgitta Kranz; Daniel Bamborschke; Sabrina Baig; Bärbel Lange-Sperandio; Theresa Jungraithmayr; Lutz T Weber; Markus J Kemper; Burkhard Tönshoff; Peter F Hoyer; Martin Konrad; Stefanie Weber
Journal:  Clin J Am Soc Nephrol       Date:  2015-12-14       Impact factor: 8.237

Review 8.  Recent advances in the management of Wilms' tumor.

Authors:  Roberto I Lopes; Armando Lorenzo
Journal:  F1000Res       Date:  2017-05-12

9.  Screening of WT1 mutations in exon 8 and 9 in children with steroid resistant nephrotic syndrome from a single centre and establishment of a rapid screening assay using high-resolution melting analysis in a clinical setting.

Authors:  Annes Siji; Varsha Chhotusing Pardeshi; Shilpa Ravindran; Ambily Vasudevan; Anil Vasudevan
Journal:  BMC Med Genet       Date:  2017-01-10       Impact factor: 2.103

Review 10.  Treatment of Genetic Forms of Nephrotic Syndrome.

Authors:  Markus J Kemper; Anja Lemke
Journal:  Front Pediatr       Date:  2018-03-26       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.